Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q3 2022 · 10-Q
Revenue$131.00M$131.00M−2.0% vs Q3 2021 Net Income-$26.58M-$26.58MN/M vs Q3 2021 EPS Diluted-$0.25-$0.25N/M vs Q3 2021 Gross Profit$101,249,000−2.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow$22,420,000−8.1% Free Cash Flowderived$16,717,000−20.8% Margins · derivedGross margin77.3%−0.1 pt vs Q3 2021
Operating margin-18.8%−12.4 pt vs Q3 2021
Net margin-20.3%−10.5 pt vs Q3 2021
ended Sep 30, 2022 · filed Oct 27, 2022 · 27 d after period end